The Amyloidosis Research Consortium is pleased to announce that the upcoming amyloidosis patient-focused forum with the FDA will be webcast live on
Monday, November 16th from 9:00 am - 3:00 pm EST.
Registration is required to view the webcast.
To view the meeting click here
Under the guidance of the U.S. Food & Drug Administration (FDA), the Amyloidosis Research Consortium (ARC) is convening a public patient and expert forum to stimulate increased understanding of amyloidosis.
Building on ARC's successful scientific roundtable meeting in mid-September 2015,
the policy forum is the second step in the framing of draft guidance on
amyloidosis drug development to be submitted for review to the FDA.
the policy forum is the second step in the framing of draft guidance on
amyloidosis drug development to be submitted for review to the FDA.
ARC is committed to ensuring that the patient voice is heard and reflected at all stages of drug discovery and development and that regulatory policy meets the expectations of our patients and families.
There will be opportunities to share your comments after the event.
To find out more, please visit:
To find out more, please visit: